ストックスクリーナーアプリを入手
10.81
1.73%
-0.19
プレマーケット:
10.52
-0.29
-2.68%
前日終値:
$11.00
開ける：
$11.01
24時間の取引高:
311.89K
Relative Volume:
0.96
時価総額：
$579.38M
収益：
$2.22M
当期純損益:
$-40.51M
株価収益率:
-8.4144
EPS:
-1.2847
ネットキャッシュフロー:
$-46.53M
1週間 パフォーマンス:
-3.57%
1か月 パフォーマンス:
-33.31%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$10.50
$11.26
1週間の範囲:
$10.41
$12.06
52週間の値動き範囲:
$10.36
$29.46
Upstream Bio Inc Stock (UPB) Company Profile
UPB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
10.81 | 579.38M | 2.22M | -40.51M | -46.53M | -1.2847 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-05 | 開始されました | JP Morgan | Overweight |
| 2024-11-05 | 開始されました | Piper Sandler | Overweight |
| 2024-11-05 | 開始されました | TD Cowen | Buy |
| 2024-11-05 | 開始されました | William Blair | Outperform |
Upstream Bio Inc (UPB) 最新ニュース
Upstream Bio (NASDAQ:UPB) Trading Down 10.4%Time to Sell? - MarketBeat
Upstream Bio (NASDAQ:UPB) Sets New 1-Year LowWhat's Next? - MarketBeat
Upstream Bio (NASDAQ:UPB) Stock Price Down 7%What's Next? - MarketBeat
Upstream Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Upstream Bio (NASDAQ:UPB) Trading Up 8.5%Here's Why - MarketBeat
CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs - MSN
Upstream Bio (NASDAQ:UPB) Trading Down 3%Here's What Happened - MarketBeat
Upstream Bio (NASDAQ:UPB) Shares Up 5.7%Time to Buy? - MarketBeat
Should You Scoop Up This 'Strong Buy' Biotech Before December 23? - MSN
Amgen Inc (AMGN-Q) QuotePress Release - The Globe and Mail
Upstream Bio (NASDAQ:UPB) Reaches New 52-Week LowShould You Sell? - MarketBeat
Newly Public Biotech Startup Hires Life Sciences Veteran as GC - Law.com
Upstream Bio (NASDAQ:UPB) Shares Gap DownWhat's Next? - MarketBeat
Upstream Bio Appoints Allison Ambrose as General Counsel - citybiz
Upstream Bio (NASDAQ:UPB) Shares Down 5%Time to Sell? - MarketBeat
Upstream Bio: Treating Respiratory Disorders With TSLP Targeting Differentiation (UPB) - Seeking Alpha
Upstream Bio To Be Added To Russell 2000 - MENAFN.COM
Upstream Bio to be Added to Russell 2000 - Baystreet.ca
Upstream Bio Announces Addition to Russell 2000® Index - GlobeNewswire
Upstream Bio to Join Russell 2000® Index, Gaining Access to $10.5T Benchmark-Linked Assets - StockTitan
Upstream Bio: Attractive, But Let's Wait For More Data And Lock-Up Expiry (NASDAQ:UPB) - Seeking Alpha
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - MSN
Upstream Bioprocessing Market to Reach USD 82.10 Billion by 2032 from USD 22.79 Billion in 2023 | CAGR of 15.35% - GlobeNewswire
Upstream Bio to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Upstream Bio CEO to Present at Piper Sandler Healthcare Conference Dec 3 | UPB Stock News - StockTitan
Upstream Bioprocessing Industry Analysis and Forecast, - GlobeNewswire
Upstream Bio, Inc.’s (NASDAQ:UPB) Quiet Period Set To End on November 20th - Defense World
Upstream Bio, Inc.'s (NASDAQ:UPB) Quiet Period Set To End on November 20th - MarketBeat
Brokers Set Expectations for Upstream Bio Q4 Earnings - MarketBeat
Upstream Bio Advances Clinical Trials, Strengthens Financials - TipRanks
Tezspire Phase III Nasal Polyp Data May Lead To Second Indication - Scrip
William Blair Weighs in on Upstream Bio Q4 Earnings - Defense World
Upstream Bio Inc (UPB) Quarterly 10-Q Report - Quartz
Upstream Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewswire
FMR LLC Acquires New Stake in Upstream Bio Inc - GuruFocus.com
Severe Asthma Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve
Upstream Bio initiated with an Overweight at Piper Sandler - MSN
Discover the 3 Best-Performing Biotech IPO Stocks of 2024 - MarketBeat
Here are Tuesday's biggest analyst calls: Apple, Microsoft, Palantir, Eli Lilly, Broadcom, Krispy Kreme, Live Nation & more - Head Topics
Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On Efficacy, Analysts Say - Benzinga
Upstream Bio initiated with an Overweight at JPMorgan - MSN
Upstream Bio Inc (UPB) 財務データ
収益
当期純利益
現金流量
EPS
Upstream Bio Inc (UPB) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ORBIMED ADVISORS LLC | Director |
Oct 15 '24 |
Buy |
17.00 |
825,000 |
14,025,000 |
4,554,873 |
| AI Upstream LLC | 10% Owner |
Oct 15 '24 |
Buy |
17.00 |
1,175,000 |
19,975,000 |
1,175,000 |
4.81%
大文字化:
|
ボリューム (24 時間):